Tag: atezolizumab

US FDA grants Breakthrough Therapy Designation for combination immunotherapy in HCC...

Roche has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)...

Interventional oncology should identify “unmet immunotherapy needs”

Daniel Sze, speaking at the ninth annual Symposium on Clinical Interventional Oncology (CIO; 4–5 February 2017, Hollywood, USA), noted that immunotherapy is a “huge...